“We have to prepare ourselves for the idea that we do not have a very good vaccine. My guess is the first is the first generation of vaccines may be mediocre, “ Micheal S. Kinch, an expert in drug development and research at Washington University in St. Louis, was quoted saying.

He cited the HIV/AIDS epidemic that saw a first generation of “fairly mediocre drugs”.

Natalie E. Dean, a biostatistician at the University of Florida, was quoted saying: “You can make something work perfectly in the lab; it’s a whole other thing to make it work out in the community.”

The measles vaccine is 98 percent at preventing the disease. However, the flu vaccine is only 40 to 60 percent effective, as those with a weaker immune system, such as the elderly, require a special high-dose flu vaccine.

“We have to prepare ourselves for the idea that we do not have a very good vaccine. My guess is the first is the first generation of vaccines may be mediocre, “ Micheal S. Kinch, an expert in drug development and research at Washington University in St. Louis, was quoted saying.

He cited the HIV/AIDS epidemic that saw a first generation of “fairly mediocre drugs”.

Natalie E. Dean, a biostatistician at the University of Florida, was quoted saying: “You can make something work perfectly in the lab; it’s a whole other thing to make it work out in the community.”

The measles vaccine is 98 percent at preventing the disease. However, the flu vaccine is only 40 to 60 percent effective, as those with a weaker immune system, such as the elderly, require a special high-dose flu vaccine.

Research shows the immune system reaction to the virus is short-lived, with antibodies lasting only two to three months versus three to 12 months for other viruses, indicating that it might be difficult to develop a long-lasting vaccine.

Research shows the immune system reaction to the virus is short-lived, with antibodies lasting only two to three months versus three to 12 months for other viruses, indicating that it might be difficult to develop a long-lasting vaccine.

Tracing 80% of contacts could be near-impossible to achieve in regions still grappling with thousands of new infections a week — and worse, even the highest case counts are likely to be an underestimate.

Tracing 80% of contacts could be near-impossible to achieve in regions still grappling with thousands of new infections a week — and worse, even the highest case counts are likely to be an underestimate.

If immunity to the virus lasts less than a year, for example, similar to human coronaviruses in circulation, there could be annual surges in COVID-19 infections through to 2025 and beyond.

If immunity to the virus lasts less than a year, for example, similar to human coronaviruses in circulation, there could be annual surges in COVID-19 infections through to 2025 and beyond.

The discovery of a vaccine to prevent Covid-19 disease will also help keep demand elevated because glove companies and some experts have noted that the widespread administering of a vaccine will actually result in a further spike in glove demand.

The discovery of a vaccine to prevent Covid-19 disease will also help keep demand elevated because glove companies and some experts have noted that the widespread administering of a vaccine will actually result in a further spike in glove demand.

https://www.independent.co.uk/voices/pfizer-vaccine-coronavirus-covid-immunity-b1719710.html

https://www.independent.co.uk/voices/pfizer-vaccine-coronavirus-covid-immunity-b1719710.html

KUALA LUMPUR: Order visibility of glove makers is expected to continue at least until the first half of 2021 on the back of the current strong demand for glove globally.

CGS-CIMB analyst Walter AW said the acute global shortage of gloves was likely to worsen as Covid-19 cases worldwide had shown no signs of slowing down.

"Many developed markets (with high glove usage per capita), such as the United States and United Kingdom have continued to record new highs in daily Covid-19 cases.

"We expect the situation to worsen as more western countries head towards the wintering period in fourth-quarter (Q4) of 2020, which could lead to further spikes in Covid-19 cases," he said in a research note recently.

Walter said acute shortage would drive higher average selling prices (ASPs) for gloves until the first-quarter (Q1) of 2021 due to the increase in raw material prices.

Based on the research firm's estimates, glove ASPs could rise between 10 per cent and 45 per cent quarter-on-quarter (QoQ) in Q4 of 2020 to US$50 to US$100 per 1,000 pieces," he said.

However, Walter said certain glove buyers were willing to offer fixed ASPs (at a substantial premium to current ASPs) with a minimum one-year contract tenure to secure glove supply.

"In our view, this should provide certainties of ASPs for 2021 if glove makers agree to these contracts."

KUALA LUMPUR: Order visibility of glove makers is expected to continue at least until the first half of 2021 on the back of the current strong demand for glove globally.

CGS-CIMB analyst Walter AW said the acute global shortage of gloves was likely to worsen as Covid-19 cases worldwide had shown no signs of slowing down.

"Many developed markets (with high glove usage per capita), such as the United States and United Kingdom have continued to record new highs in daily Covid-19 cases.

"We expect the situation to worsen as more western countries head towards the wintering period in fourth-quarter (Q4) of 2020, which could lead to further spikes in Covid-19 cases," he said in a research note recently.

Walter said acute shortage would drive higher average selling prices (ASPs) for gloves until the first-quarter (Q1) of 2021 due to the increase in raw material prices.

Based on the research firm's estimates, glove ASPs could rise between 10 per cent and 45 per cent quarter-on-quarter (QoQ) in Q4 of 2020 to US$50 to US$100 per 1,000 pieces," he said.

However, Walter said certain glove buyers were willing to offer fixed ASPs (at a substantial premium to current ASPs) with a minimum one-year contract tenure to secure glove supply.

"In our view, this should provide certainties of ASPs for 2021 if glove makers agree to these contracts."

KUALA LUMPUR: Hartalega Holdings Bhd says demand for rubber gloves won’t be affected by vaccines for the Covid-19 coronavirus and will continue to outstrip supply in the next three to four years.

The pandemic has changed users’ behavior, that has resulted in the demand for gloves, chairman Kuan Kam Hon told reporters. Demand for usage in developed countries have increased 30% while in developing countries, usage has more than doubled, he says.

The industry cannot meet the 120b of additional demand for gloves. This demand can only be fulfilled in three years, he adds.

Spot prices for gloves have jumped 30% this quarter and he expects them to increase 40-50% in coming quarters, he says.

Glove prices are now three times higher compared to those during pre-covid-19.

Hartalega earmarked RM1.5bil investment to build four plants, of which first two lines will be operational by October 2021.

Another RM3bil is for its next expansion phase, its so-called NGC2, which will be fully completed in seven years. - Bloomberg

KUALA LUMPUR: Hartalega Holdings Bhd says demand for rubber gloves won’t be affected by vaccines for the Covid-19 coronavirus and will continue to outstrip supply in the next three to four years.

The pandemic has changed users’ behavior, that has resulted in the demand for gloves, chairman Kuan Kam Hon told reporters. Demand for usage in developed countries have increased 30% while in developing countries, usage has more than doubled, he says.

The industry cannot meet the 120b of additional demand for gloves. This demand can only be fulfilled in three years, he adds.

Spot prices for gloves have jumped 30% this quarter and he expects them to increase 40-50% in coming quarters, he says.

Glove prices are now three times higher compared to those during pre-covid-19.

Hartalega earmarked RM1.5bil investment to build four plants, of which first two lines will be operational by October 2021.

Another RM3bil is for its next expansion phase, its so-called NGC2, which will be fully completed in seven years. - Bloomberg

https://www.theedgemarkets.com/article/top-glove-give-rm185m-govt-fight-covid19

Top Glove to give RM185m to govt to fight Covid-19

U.S. reports nearly 90,000 new coronavirus cases amid surges in every swing state.

U.S. reports nearly 90,000 new coronavirus cases amid surges in every swing state

The Average Selling Prices (ASPs) are continuing to trend upwards and the highest ASPs have not been reflected in this current quarter. We are optimistic that our OBM cum Distribution Business Model will exhibit even healthier & stellar performances in the
coming quarters.

Well done and congrats!

WASHINGTON: The United States saw a record high number of new daily COVID-19 cases for the second day in a row on Saturday (Oct 24), figures from Johns Hopkins University showed, as warnings grew over its spread.

The country reported 88,973 new infections between 8.30pm Friday and 8.30pm Saturday local time, the figures showed, substantially above the previous day's 79,963.

US sees record COVID-19 numbers for second day straight.

A third surge of coronavirus infections has now firmly taken hold across much of the United States.

It's also still not known how long the immunity gained through any of the current COVID-19 vaccine candidates will last or to what extent the virus might mutate or change in a way that makes that vaccine less effective.

There are logistical challenges to getting everyone vaccinated, given the mammoth undertaking of manufacturing and distributing a vaccine.

50 out of 100 people who get the vaccine could still end up getting infected with the coronavirus.

A vaccine will not be a magic bullet. In fact, it may be only about 50% effective.

— Nearly 96,000 people have been fined in Moscow for violating mask and glove-wearing requirements on public transport since May, a city transport official told the state-run TASS news agency Tuesday.

Silver bullet?

We can’t be sure that vaccines will mean an end to lockdowns. Scientists advise politicians to lock down to prevent the virus spreading so fast that hospitals run out of beds to treat the sick – whether they have Covid-19 or another life-threatening illness. The first vaccines may only be partially effective, and may not protect everyone. Flu vaccines are only 50% effective.

Does immunity protect an individual from disease on reinfection? The answer is not necessarily, because patients from Nevada and Ecuador had worse disease outcomes at reinfection than at first infection.

SARS-CoV-2 reinfection resulted in worse disease than did the first infection, requiring oxygen support and hospitalisation.

Study published in The Lancet Infectious Diseases journal indicated that exposure to the virus may not guarantee future immunity — and the second infection could come with even more severe symptoms.

https://www.theedgemarkets.com/article/glove-makers-remain-favourites-politicaltheme-play-put-penny-stocks-roller-coaster-rides

UK coronavirus live: 19,724 new cases recorded, a daily rise of nearly 2,500

Number of covid-19 infections continues to rise in Italy.

Covid-19 vaccine by no means a cure-all, public health experts warn

https://www.malaymail.com/news/malaysia/2020/10/06/covid-19-vaccine-by-no-means-a-cure-all-public-health-experts-warn/1909942

Dont sell, dont help the market makers.

Market makers double up as syndicates = manipulators.

Glove demand remains at a “supernormal level”, Top Glove said in a statement, estimating demand to grow 25 per cent next year and 15 per cent post-pandemic.

The firm said the protective gear would still be required when a vaccine becomes available.

Superb result.

62 new Covid-19 infections, 56 local transmissions

Wrong information/interpretation by the newspaper.

Read carefully the news from bursa website.

Announcement details

Freezing of Upper Limit Price for IQGROUP HOLDINGS BHD (5107) - 2 September 2020

Please be informed that the Upper Limit Price of the following counter will be maintained as below in accordance to the Rules of Bursa Malaysia Securities, Chapter 8 TRADING, STATIC PRICE LIMITS (8.13(5)) and Trading Manual Chapter 4, Reference Price And Price Limits (4.3) Freezing of Price, due to the counter trading at Static Limit Upper Price for two (2) consecutive trading days:


Stock Short Name/Code Upper limit


1. IQGROUP (5107) RM 1.05

Freezing of Upper Limit Price for IQGROUP HOLDINGS BHD (5107) - 2 September 2020

Freeze for 1 day only, 2 September.

Stupid Trump.

On Tuesday, VSI said it had signed an agreement with US-based Victory Innovations Company Inc to manufacture and supply cordless electrostatic sprayers on a box-built basis.

Victory’s products, cordless electrostatic handheld sprayers and cordless electrostatic backpack sprayers, are used by hospitals, hotels, schools, airlines, casinos, public transportation, households and businesses to sanitise and disinfect large areas swiftly and effectively.

Wow!